Proteome Sciences Licenses TMT Technology to Thermo Fisher
Proteome Sciences this week announced it has exclusively licensed its isobaric mass-labeling technology to Thermo Fisher Scientific.
Under the terms of the agreement, Proteome Sciences will manufacture the Tandem Mass Tag reagents exclusively for Thermo Fisher, who will market and sell them worldwide through its Pierce Biotechnology unit. Proteome Sciences will receive signature fees, contract manufacturing payments, royalties, and milestone payments.
Further details of the agreement were not disclosed.
Proteome Sciences said it expects double-digit growth in the market for isobaric mass tags. In a statement, Christopher Pearce, CEO of the company, said, “The agreement with Thermo Fisher provides Proteome Sciences with a strong cash flow, which transforms the prospects for our company with sustainable, rising revenue from all areas of our activities.”
Ian Jardine, vice president of global research and development for Thermo Fisher, said TMT products will be available in the second quarter.
Proteome Sciences received patent rights for the technology in parts of Europe and in the US during the past year and has since been in negotiations to license it. Last month, Applera filed an opposition with the European Patent Office, saying the patent should be revoked in full because it was neither novel nor contained any new inventive procedures [See PM 03/27/08].
Proteome Sciences has said that the grounds of the opposition had been addressed and dismissed earlier, but was reviewing Applera’s opposition and would offer a response upon completion.
Invitrogen Becomes MitoSciences North American Distributor
Invitrogen said this week it is becoming the exclusive North American distributor of MitoSciences products, including antibodies and assay for research into mitochondrial proteins and diseases.
MitoSciences has the world’s largest collection of anti-mitochondrial monoclonal antibodies and immunoassays, the companies said in a statement.
As existing MitoSciences distribution agreements expire, Invitrogen will take on the agreements on a worldwide basis. The deal adds more than 200 new products to Invitrogen’s antibody and kit catalog.
Terms of the deal were not released.
Varian Buys Oxford Diffraction for $37M
Varian this week purchased X-ray crystallography firm Oxford Diffraction for approximately $37 million.
The deal is structured as a cash and debt-assumption transaction. Varian could also pay Oxford an additional $10 million based on future financial performances during the next three years. For the 12 months ended March 31, Oxford generated revenues of $15 million.
The deal is part of Varian’s strategy to “strengthen the company’s portfolio of information-rich detection products through internal research and development as well as the acquisition of complementary products and technologies,” the company said in a statement.
South African Proteomic and Genomic Research Facility Opens
The Center for Proteomic and Genomic Research at the University of Cape Town’s medical campus opened last week.
The center is focused on researching molecular diagnostic markers for diseases such as malaria, leukemia, and colorectal cancer, and is the first proteomic and genomics research facility in South Africa.
Ariadne Licenses Pathway Studio Enterprise to German University
The Albert-Ludwigs University of Freiburg has licensed Ariadne’s Pathway Studio Enterprise system, the company said this week.
The system includes the ResNet database of molecular interactions extracted from the whole of PubMed. The university will use it to support its mammalian, worm, and plant research.
Terms of the deal were not disclosed.
CST Opens Tokyo Subsidiary
Cell Signaling Technology this week announced it has opened a wholly owned subsidiary in Tokyo and began fulfilling orders on April 1.
The Tokyo office is the first step in the company’s strategy to establish a presence in key global markets, said Fenel Eloi, the company’s COO, in a statement.